RPG Life Sciences Limited — PPTs, 02-09-2026: Investor Presentation

RPG Life Sciences has strategically spun off its Active Pharmaceutical Ingredients (API) business into a new subsidiary, RPG Active Pharma (RPGAP). This move aims for sharper focus and growth. The API unit recorded ~95.1 Cr in external sales in FY26, specializing in high-value niche products.

In a key development, RPGAP partnered with pharma-focused PE firm InvAscent, securing ~243.33 Cr for a 40% stake. This brings growth capital and sector expertise. RPGAP also expanded aggressively, acquiring Actis Generics for ~80 Cr and Raghava Life Sciences for ~135 Cr. These acquisitions significantly boost its product portfolio, R&D capabilities, and manufacturing capacity, which has now quadrupled. Raghava Life Sciences alone has a revenue potential of ~200 Cr at full utilization.

Management sees RPGAP as future-ready, with strong liquidity, zero debt, and modern facilities, poised to leverage economies of scale and drive value creation.